Merck & Co., Inc. (NYSE:MRK) Stock Price Down 1.4% – What’s Next?

Merck & Co., Inc. (NYSE:MRK) shares traded down 1.4% on Tuesday . The stock traded as low as $118.61 and last traded at $119.67. 9,283,799 shares were traded during trading, a decline of 28% from the average session volume of 12,971,464 shares. The stock had previously closed at $121.41.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Robust Keytruda clinical results and approvals: multiple Phase 3 KEYTRUDA combination wins (renal cell, bladder, ovarian) showed survival benefits that have already led to U.S./EU approvals and priority reviews — supports continued revenue growth and near-term commercial momentum. Merck Keytruda Combos Strengthen Oncology Platform And Raise Patent Questions
• Positive Sentiment: Strategic AI collaboration with Tempus: Merck signed a multi‑year deal to accelerate AI-driven precision medicine development — could improve R&D efficiency, biomarker identification, and long‑term pipelines. AI-Powered Tempus Inks New Multi-Year Merck Deal
• Positive Sentiment: Value/analyst narrative remains constructive: market commentary highlights MRK as potentially undervalued (P/E well below industry), with continued Keytruda-driven growth, new product (Enflonsia RSV) momentum, and a corporate split to diversify post‑Keytruda. That supports buy-side interest. 3 Undervalued Names Too Cheap to Ignore (Merck section)
• Neutral Sentiment: Investor presentation transcript released at TD Cowen conference — useful management commentary and pipeline color but no surprise financials; read for execution/strategy details. Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Neutral Sentiment: Analyst coverage and Wall Street views: media pieces discuss bullish analyst sentiment and whether that supports a buy decision — relevant for flows but not an immediate catalyst. Is It Worth Investing in Merck (MRK) Based on Wall Street’s Bullish Views?
• Neutral Sentiment: Peripheral industry news (e.g., MXene materials report) is not material to Merck’s fundamentals. MXene Industry Research Report 2026
• Negative Sentiment: Patent/IP risk for Keytruda: Keytruda is ~55% of MRK’s pharma sales — outstanding clinical success but concentration raises vulnerability ahead of patent expirations and potential biosimilar competition (patent questions flagged). This is a major medium-term risk to revenue and valuation. Merck’s Keytruda Drives its 2025 Revenue Surge: What’s Ahead?
• Negative Sentiment: Near-term price pressure: the shares have recently dipped while the broader market gained, reflecting profit‑taking and investor concerns about concentration/patent risk despite positive clinical and strategic news. Merck (MRK) Stock Dips While Market Gains: Key Facts

Analysts Set New Price Targets

Several research firms have commented on MRK. Scotiabank upped their price objective on Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “sector outperform” rating in a research report on Thursday, December 4th. Zacks Research cut shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a report on Friday, January 9th. Citigroup increased their target price on shares of Merck & Co., Inc. from $115.00 to $120.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. The Goldman Sachs Group lifted their price target on Merck & Co., Inc. from $92.00 to $120.00 and gave the company a “buy” rating in a research note on Tuesday, December 2nd. Finally, Wolfe Research raised Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price target for the company in a report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $125.88.

Merck & Co., Inc. Trading Down 1.4%

The company has a market capitalization of $295.87 billion, a PE ratio of 16.44, a price-to-earnings-growth ratio of 2.40 and a beta of 0.27. The company has a 50 day simple moving average of $113.27 and a 200 day simple moving average of $97.77. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The business had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. During the same quarter last year, the business posted $1.72 earnings per share. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.

Insider Buying and Selling

In other news, EVP Richard R. Deluca sold 37,685 shares of the business’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the transaction, the executive vice president directly owned 160,174 shares in the company, valued at $19,368,240.08. The trade was a 19.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $121.87, for a total value of $1,828,050.00. Following the completion of the sale, the insider directly owned 21,197 shares of the company’s stock, valued at approximately $2,583,278.39. This represents a 41.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 320,176 shares of company stock worth $38,281,735 in the last 90 days. Corporate insiders own 0.09% of the company’s stock.

Institutional Investors Weigh In On Merck & Co., Inc.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Merck & Co., Inc. by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock valued at $26,770,014,000 after purchasing an additional 2,185,853 shares during the period. State Street Corp increased its position in shares of Merck & Co., Inc. by 1.6% during the fourth quarter. State Street Corp now owns 120,040,168 shares of the company’s stock valued at $12,737,504,000 after acquiring an additional 1,859,990 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Merck & Co., Inc. by 14.8% in the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock valued at $9,098,196,000 after acquiring an additional 11,156,354 shares during the period. Geode Capital Management LLC raised its stake in shares of Merck & Co., Inc. by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock valued at $6,307,572,000 after acquiring an additional 249,110 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Merck & Co., Inc. by 9.4% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 53,865,466 shares of the company’s stock worth $4,263,991,000 after acquiring an additional 4,636,183 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.